~ Top Universities to Test New Technology Targeting Prostate Cancer
PR Newswire, 09-20-05
ST. LOUIS, Sept 20, 2005 /PRNewswire via COMTEX/ -- Ten top hospitals, including seven of the nation's leading urological centers, announced they will test a new FDA-approved prostate diagnostic and treatment device in the hopes of achieving earlier detection of prostate cancer. The Prostate Cancer Biopsy Study will utilize the TargetScan(TM) Bendable Needle and Guide System, proving the device's efficacy in identifying cancer from the first biopsy, versus conventional techniques which can leave cancer undetected for up to three biopsies.
Participating universities include: Washington University School of Medicine, New York University School of Medicine, the University of Texas Southwestern Medical College, University of California at San Francisco, University of Southern California - Norris Cancer Center, Vanderbilt University Medical Center, and the University of Michigan.
The 900-patient clinical study will compare TargetScan's biopsy results to clinical outcomes derived from current biopsy methods. A previous pilot study, conducted in May 2005 at Washington University in St. Louis, found that TargetScan biopsy samples better predict Gleason scores (the most commonly used prostate cancer grading system) compared to traditional biopsy techniques -- promoting more accurate and earlier identification of cancer. The study also concluded that TargetScan's ability to conduct repeatable biopsies could significantly impact the success of new cancer-treatment deliveries, such as brachytherapy and cryotherapy, which reduce the risks of post-treatment side effects.
Following the current clinical evaluation, TargetScan's developer, St. Louis-based Envisioneering Medical Technologies, will commercially launch the device for clinical use in the 1.3 million prostate biopsy procedures performed annually in the United States.
"We heard the industry's call for a better biopsy strategy to provide patients with conclusive test results from the first biopsy," said Robert G. Mills, Envisioneering president. "With this study, we are one step closer to offering physicians and patients an effective means for the early detection of prostate cancer. With rapid detection, physicians can offer patients more treatment options, which inherently enhance the patient's survival rate and reduces the risks of post-treatment side effects."
How TargetScan Works
Combining 3-D image acquisition with a stationary probe, TargetScan allows physicians to plan and execute targeted prostate biopsies using a patented bendable biopsy needle. Comparably, current procedures require urologists to hold and pivot a probe with one hand while performing a needle biopsy with the other hand-forcing physicians to miss potential cancers.
About Envisioneering Medical Technologies
Based in St. Louis, Mo., Envisioneering Medical Technologies is dedicated to developing, manufacturing and marketing proprietary diagnostic and treatment technologies for the physician community. For more information, please visit http://www.envisioneeringmedical.com .
SOURCE Envisioneering Medical Technologies
CONTACT: Cheri Winchester for Envisioneering Medical Technologies, +1-636-530-1235, or
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.